- The FDA designates AstraZeneca's (NYSE:AZN) selumetinib an Orphan Drug for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye. It is the most common primary intraocular malignancy in adults. The incidence is 4.3 cases per 1M people and peaks near the age of 70.
- Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.
AstraZeneca's selumetinib an Orphan Drug for eye cancer
Recommended For You
More Trending News
About AZN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AZN | - | - |
AstraZeneca PLC |